Several new articles have recently been published on the cost of respiratory syncytial virus (RSV) and the cost-effectiveness of RSV prevention and management. Learn about these below.
-
Mahmud S, Baral R, Sanderson C, Pecenka C, Jit M, Li Y, Clark A. Cost‑effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus in young children: a decision-support model for use in low- and middle‑income countries. BMC Medicine 2023.
-
Wittenauer R, Pecenka C, Baral R. Cost of childhood RSV management and cost‑effectiveness of RSV interventions: a systematic review from a low‑ and middle‑income country perspective. BMC Medicine 2023.
-
Do L, Vodicka E, Nguyen A, Le T, Nguyen TTH, Thai Q, Pham V, Pham T, Nguyen TN, Mulholland K Cao M, Le N, Tran A, Pecenka C. Estimating the economic burden of respiratory syncytial virus infections in infants in Vietnam: a cohort study. BMC Infectious Diseases 2023.
-
Nyawanda BO, Murunga N, Otieno NA, Bigogo G, Nyiro JU, Vodicka E, Nokes DJ, Munywoki P, Emukule GO. Estimates of the national burden of respiratory syncytial virus in Kenyan children aged under 5 years, 2010-2018. BMC Medicine 2023.